Bio-equivalence Study Between SAPHRIS and Asenapine
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This is a Multiple-dose, steady state, three-way reference-replicated crossover study.
The purpose of this Study is to determine the bio-equivalence between SAPHRIS and Asenapine
10mg sublingual tablets.
Phase:
Phase 1
Details
Lead Sponsor:
bioRASI, LLC Sun Pharmaceutical Industries Limited
Collaborators:
bioRASI, LLC Sun Pharmaceutical Industries Limited